CAJU Venture Partners

CAJU Venture Partners focuses exclusively on European MedTech investments, partnering with visionary entrepreneurs who demonstrate high integrity and the potential to transform healthcare delivery. The firm strategically identifies and supports innovative medical technology companies that address critical healthcare challenges and possess significant market growth potential. Through their specialized investment approach, CAJU aims to accelerate the development of breakthrough medical technologies while generating substantial returns for their investors and meaningful impact on patient outcomes.

The active CAJU Ventures Portfolio showcases a diverse range of cutting-edge medical innovations across multiple European markets. Their investments include French-based Archeon Medical, developers of an advanced manual ventilation monitoring platform enhancing pre-hospital and in-hospital care; Irish company FeelTect, which has created intelligent technology for Advanced Wound Care with an initial concentration on venous leg ulcer therapy; Spanish startup Innitius, pioneers of novel cervical tissue assessment technology for obstetric diagnostics; and Kilobaser, an American company revolutionizing DNA synthesis through their proprietary single-cartridge system technology.

The firm's previous AiG Portfolio (now closed) further demonstrates their expertise in identifying promising healthcare innovations. This portfolio included Gedea Biotech from Sweden, creators of antibiotic-free treatments for bacterial vaginosis; Irish-based Gasgon Medical, which developed award-winning fluid management products for clinical applications; NeuroCare Group from Germany, a global leader in neuromodulation therapies for mental health conditions; and two UK-based companies - Oxford Endovascular, developers of next-generation flow-diverters for intracranial aneurysms, and Orthox, which is pioneering revolutionary treatments for osteoarthritis.

What distinguishes CAJU Venture Partners in the competitive MedTech investment landscape is their extensive network of industry connections and specialized expertise. The firm provides exclusive deal sourcing through collaborations with trusted industry partners and a network of experienced trustees, giving them early access to promising investment opportunities. This strategic advantage, combined with their deep understanding of healthcare markets and regulatory environments across Europe, enables CAJU to identify high-potential medical technologies at optimal investment stages and provide portfolio companies with valuable guidance beyond mere financial support.